A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Public ClinicalTrials.gov record NCT07428616. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
Study identification
- NCT ID
- NCT07428616
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 20, 2026
- Primary completion
- Feb 28, 2028
- Completion
- Sep 29, 2029
- Last update posted
- Jul 26, 2026
2026 – 2029
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | 35294 | Recruiting |
| Mayo Clinic_Arizona | Phoenix | Arizona | 85054 | Recruiting |
| Mayo Clinic_Jacksonville | Jacksonville | Florida | 32224 | Recruiting |
| Baptist Health Miami Cancer Institute | Miami | Florida | 33176 | Recruiting |
| Washington University School of Medicine | St Louis | Missouri | 63110 | Recruiting |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| Mayo Clinic_Rochester | Rochester | New York | 55905 | Recruiting |
| Duke University | Durham | North Carolina | 27710 | Recruiting |
| UT MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| UT Health San Antonio Mays Cancer Center | San Antonio | Texas | 78229 | Recruiting |
| Inova Center for Personalized Health | Fairfax | Virginia | 22031 | Recruiting |
| UW Carbone Cancer Center | Madison | Wisconsin | 53792 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07428616, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 26, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07428616 live on ClinicalTrials.gov.